Omnicell Upgraded to Zacks Buy, Plans Feb. 5 Q4/FY2025 Results Release
Omnicell was upgraded to a Zacks Rank #2 (Buy), signaling growing analyst optimism toward its earnings outlook. The company also set February 5, 2026, as the release date for its Q4 and full-year 2025 results, with a conference call scheduled at 8:30 a.m. ET.
1. Rating Upgrade Sparks Investor Confidence
On January 22, 2026, Zacks Investment Research upgraded Omnicell to a Zacks Rank #2 (Buy), citing improved earnings estimates for the next four quarters. Analysts raised full-year 2026 EPS forecasts by an average of 8% over the past month, driven by expected strength in pharmacy automation orders. The upgrade follows a 12% increase in orders from U.S. hospital systems during Q3 2025, signaling continued momentum in the company’s key markets and bolstering optimism about revenue growth in 2026.
2. Upcoming Q4 and Full-Year 2025 Results Release
Omnicell will report fourth quarter and full-year 2025 financials before the market opens on February 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET that day (U.S. dial-in: (800) 715-9871; International: (646) 307-1963; Conference ID 4203777). Investors will be watching guidance for 2026, which is expected to reflect continued strength in automation and software subscription services that accounted for 45% of revenue growth in Q3 2025.
3. Strategic Positioning and Growth Drivers
Since its founding in 1992, Omnicell has focused on autonomous medication management by integrating robotics, AI-enabled analytics and professional services. In Q3 2025, the company deployed over 200 new automated dispensing cabinets and expanded its AI-powered analytics footprint to 150 healthcare facilities. With a backlog of $180 million as of December 2025—up 15% year-over-year—Omnicell aims to leverage its installed base to cross-sell new software modules and support services, targeting a 20% increase in recurring revenue streams in 2026.